Canadian cannabinoid developer Tetra Bio-Pharma says that it has filed a patent application covering technology related to its PPP001 cannabis drug pellet. According to the company, the patent application covers fabrication methods and composition of matter.
Tetra’s announcement says, “research demonstrated that the class II medical device or pipe used to combust the PPP001 drug pellet generates a unique composition of medicinal ingredients. This composition is significantly different from that created when heating the drug pellet in a vaporizer. The data demonstrated that the drug produced by combustion is different from that of the vapor and may partly explain the recognized efficacy of smoked cannabis. The composition of the remaining chemicals was expected to be different between smoke and vapor. This led the Corporation to implement two separate drug development paths and allow Tetra to commence developing second generation drugs for inhalation.”
Two clinical studies of PPP001 are listed on clinicaltrials.gov, one comparing inhaled PPP001 to buccal fentanyl for the treatment of breakthrough pain in cancer and one evaluating smoked PPP001 for improving quality of life in patients with advanced cancer.
Tetra Bio-Pharma CEO and Chief Scientific Officer Guy Chamberland commented, “This will give Tetra a much longer period of exclusivity. We recognize the inherent value of our intellectual property and the necessity to seek appropriate patents, to the extent possible, to protect our shareholders’ investments in the company.”
Read the Tetra Bio-Pharma press release.
